USD
$0.00
(0.00%
)At Close (As of Dec 17, 2025)
$119.23M
Market Cap
-
P/E Ratio
-0.04
EPS
$3.88
52 Week High
$1.33
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$26K |
| Total Revenue | $0 |
| Cost Of Revenue | $26K |
| Costof Goods And Services Sold | $26K |
| Operating Income | -$29M |
| Selling General And Administrative | $11M |
| Research And Development | $17M |
| Operating Expenses | $29M |
| Investment Income Net | - |
| Net Interest Income | $1.1M |
| Interest Income | $1.1M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $26K |
| Income Before Tax | -$28M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$28M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$28M |
| Ebitda | -$27M |
| Net Income | -$28M |
| Field | Value (USD) |
|---|---|
| Total Assets | $99M |
| Total Current Assets | $98M |
| Cash And Cash Equivalents At Carrying Value | $56M |
| Cash And Short Term Investments | $56M |
| Inventory | - |
| Current Net Receivables | - |
| Total Non Current Assets | $149K |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $41M |
| Other Current Assets | $908K |
| Other Non Current Assets | - |
| Total Liabilities | $3.7M |
| Total Current Liabilities | $3.7M |
| Current Accounts Payable | $943K |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $111K |
| Total Non Current Liabilities | $0 |
| Capital Lease Obligations | $111K |
| Long Term Debt | - |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $111K |
| Other Current Liabilities | $2.7M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | $95M |
| Treasury Stock | - |
| Retained Earnings | -$94M |
| Common Stock | $69K |
| Common Stock Shares Outstanding | $69M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$26K |
| Total Revenue | $0 |
| Cost Of Revenue | $26K |
| Costof Goods And Services Sold | $26K |
| Operating Income | -$29M |
| Selling General And Administrative | $11M |
| Research And Development | $17M |
| Operating Expenses | $29M |
| Investment Income Net | - |
| Net Interest Income | $1.1M |
| Interest Income | $1.1M |
| Interest Expense | - |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $26K |
| Income Before Tax | -$28M |
| Income Tax Expense | - |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$28M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$28M |
| Ebitda | -$27M |
| Net Income | -$28M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Atlanta, dedicated to advancing innovative treatments for Parkinson's disease and related neurodegenerative disorders. The company employs a distinctive dual-targeting approach to tackle both central and peripheral neurodegeneration, thereby addressing significant unmet needs in patient care. With a robust pipeline of clinical candidates, Inhibikase is well-positioned to substantially impact the treatment landscape and improve the quality of life for individuals living with these challenging conditions.